Sudarshan Sharma, MD
Gynecologic Oncology · Hinsdale, ILNPI 1740265974
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $735 and has fallen 84.3% since, to $115 in 2025.
Across 99 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$566
- AstraZeneca$413
- Eisai Inc.$355
- Intuitive Surgical$247
- Clovis Oncology, Inc.$217
- Seagen Inc.$177
- plus $524 from 13 others
Across 175 payments — averaging $14,805 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.5M
- GSK$665K
- Genentech, Inc.$202K
- AstraZeneca$148K
- Clovis Oncology, Inc.$102K
- Pharmaand GmbH$5K
- plus $4K from 2 others
What the payments were for
- Food & beverage$2,47799%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 29 | $566 |
| AstraZeneca | 12 | $413 |
| Eisai Inc. | 16 | $355 |
| Intuitive Surgical | 4 | $247 |
| Clovis Oncology, Inc. | 10 | $217 |
| Seagen Inc. | 9 | $177 |
| Genentech USA, Inc. | 2 | $128 |
| GSK | 4 | $88 |
| Baxter Healthcare | 1 | $65 |
| Pfizer | 2 | $43 |
| AbbVie | 2 | $32 |
| Celltrion USA Inc. | 1 | $31 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $19 |
| Immunogen, Inc. | 1 | $18 |
| Lumenis, Inc | 1 | $16 |
| Olympus America Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,499 in reported general payments places this provider in the 55th percentile of 64 gynecologic oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 61 | $699,259 |
| ZejulaNiraparib Tosylate | 11 | $196,027 |
| RubracaRucaparib Camsylate | 16 | $189,547 |
| PremarinEstrogens, Conjugated | 13 | $6,199 |
| Gabapentin | 26 | $526 |
| Estradiol | 14 | $366 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $361 |
| Dexamethasone | 17 | $293 |
| Warfarin Sodium | 30 | $246 |
| Ondansetron Hcl | 43 | $241 |
| Prochlorperazine Maleate | 16 | $177 |
| Zolpidem Tartrate | 20 | $143 |
| Tramadol Hcl | 21 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $413 | $699,25961 claims |
| GSKZejula | $88 | $196,02711 claims |
| Clovis Oncology, Inc.Rubraca | $217 | $189,54716 claims |
| PfizerPremarin | $43 | $6,19913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 64 gynecologic oncology providers in Illinois.
Other gynecologic oncology in Hinsdale
- Amina AhmedChicago$1.1M
- Dario RoqueChicago$587K
- Jenna MarcusChicago$230K
- Raanan AlterWarrenville$128K
- Emily HinchcliffChicago$62K
- Summer DewdneyChicago$59K
- Alfred GuirguisOak Lawn$44K
- Kathryn MillsChicago$32K
- Wilberto Nieves-NeiraChicago$23K
- Amy AlexanderChicago$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.